Chinook investor relations
WebMar 28, 2024 · The archived webcast will remain available for replay on Chinook’s website for 90 days. About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney … WebJan 31, 2024 · INVESTORS OVERVIEW. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung …
Chinook investor relations
Did you know?
WebApr 15, 2024 · Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Noopur Liffick Vice President, Investor Relations & Corporate Communications [email protected] [email protected] Source: Chinook … WebOct 15, 2024 · For more information on these and other abstracts, please visit the ASN Kidney Week 2024 website and Abstract Supplement. Investor Conference Call Details To access the call, please dial (844 ...
WebApr 11, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ... WebChinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Changing the Course of Kidney Care™ Read More
WebNov 4, 2024 · Chinook to host investor conference call and webcast today at 4:30 pm EDT with Jonathan Barratt, MChB, PhD, Mayer Professor of Renal Medicine at University of Leicester, and Laura Kooienga, MD ... Web2 days ago · To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. …
Web1 day ago · Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) ... Investor Relations & Corporate Communications [email protected] [email protected] Apr 10, 2024 COMTEX ...
WebOct 5, 2024 · Prior Chinook stockholders collectively own approximately 39.5% of the combined company, prior Aduro stockholders collectively own approximately 39.9% of the combined company and investors in the ... chinese food 60601Web2 days ago · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development … chinese food 60607WebAtrasentan. Atrasentan is a potent and selective endothelin A (ETA) receptor antagonist that is currently being evaluated in a phase 3 registration trial (ALIGN) for IgA nephropathy and a phase 2 open-label basket trial (AFFINITY) of proteinuric glomerular diseases, including IgA nephropathy, FSGS, Alport syndrome and DKD. Learn More. chinese food 60506Web2 days ago · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor … grand hotel tynemouthWebApr 11, 2024 · Investor Relations ... About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s ... chinese food 59th and kedzieWebNoopur Liffick is Senior Vice President of Investor Relations and Corporate Communications at Chinook Therapeutics. With over 17 years of investor relations, … chinese food 60004WebDec 1, 2024 · Chinook Therapeutics To Form SanReno Therapeutics. 50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China. Expands global reach and execution for Chinook’s atrasentan and BION-1301 programs in IgA nephropathy (IgAN) SEATTLE , Nov. 30, 2024 (GLOBE NEWSWIRE) — … chinese food 610 stafford va